Boylan James P 4
4 · Immunome Inc. · Filed Oct 31, 2023
Insider Transaction Report
Form 4
Immunome Inc.IMNM
Boylan James P
Director
Transactions
- Award
Stock option (right to buy)
2023-10-27+41,538→ 41,538 totalExercise: $8.73Exp: 2033-10-26→ Common Stock (41,538 underlying)
Footnotes (3)
- [F1]Mr. Boylan waived the initial grant provided for under the Company's non-employee director compensation policy in effect on the date he joined the Company's board of directors pending the adoption of an amended and restated non-employee director compensation policy (the "New NED Compensation Policy"). On October 27, 2023, the compensation committee of the Company's board of directors adopted and approved the New NED Compensation Policy. The above reflects Mr. Boylan's initial grant under the New NED Compensation Policy.
- [F2]The options vest in 12 quarterly installments over three years, commencing on October 2, 2023 and continuing thereafter on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.
- [F3]Mr. Boylan has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the reported securities.